20.500.12556/RUL-110000
Farmakogenetika lajšanja pooperativne bolečine s tramadolom
Pharmacogenetics of postoperative pain management with tramadol
Tramadol je centralno delujoč opioidni analgetik za lajšanje akutnih in kroničnih bolečin. Encimi CYP2D6, UGT2B7, ABCB1 in ABCC2 so ključni za presnovo in transport tramadola. Polimorfizmi v genih za te encime bi lahko vplivali na farmakokinetiko tramadola in s tem na odgovor na zdravljenje. Namen raziskave je bil preveriti pogostnost teh polimorfizmov in njihov vpliv na odgovor na zdravljenje pri bolnicah po operaciji raka dojke. Preverili smo hipotezi, da je pogostost neželenih učinkov pri slabih presnavljalkah CYP2D6 manjša kot pri hitrih ali ultrahitrih presnavljalkah in da imajo nosilke polimorfizmov ABCB1, ABCC2 in UGT2B7 večje tveganje za pojav neželenih učinkov kot preiskovanke brez polimorfnih alelov. Pri 113 preiskovankah smo s kvantitativnim PCR določili frekvence alelov CYP2D6: *3, *4, *5, *6, *10, *41 in *2xN, ABCB1 rs1128503, rs2032582 in rs1045642, ABCC2 rs2804402, rs717620 in rs2273697 in UGT2B7 rs7668258 in rs7668258, ter s statistično analizo preverili njihov vpliv na prekinitev zdravljenja in pojav neželenih učinkov. Bolnice homozigotne za polimorfni alel UGT2B7 rs28365063 GG so statistično značilno pogosteje prekinile zdravljenje zaradi neželenih učinkov. Vmesne in hitre presnavljalke CYP2D6 so statistično značilno pogosteje poročale o zaprtju (P=0,005). Vplivi ostalih preučevanih polimorfizmov na tveganje za prekinitev zdravljenja ali pojav neželenih učinkov niso bili statistično značilni.
Tramadol is a central-acting opioid analgesic for the relief of acute and chronic pain. CYP2D6, UGT2B7, ABCB1 and ABCC2 enzymes are crucial for the metabolism and transport of tramadol. Polymorphisms in the genes for these enzymes could affect the pharmacokinetics of tramadol and hence the response to treatment. The aim of the study was to determine the frequency of these polymorphisms and their impact on treatment response in patients following breast cancer surgery. We hypothesized that frequency of adverse events is lower in poor CYP2D6 metabolizers than in fast or ultrafast metabolizers and that ABCB1, ABCC2 and UGT2B7 polymorphisms confer to a greater risk of adverse effects than non-polymorphic allele . In 113 patients, the frequencies of CYP2D6 * 3, * 4, * 5, * 6, * 10, * 41 and * 2xN, ABCB1 rs1128503, rs2032582 and rs1045642, ABCC2 rs2804402, rs717620 and rs2273697 and UGT2B7 rs7668258 and rs7668258 were determined by quantitative PCR. Statistical analysis was used to assess the associations with treatment discontinuation and the occurrence of adverse events. Patients homozygous for polymorphic UGT2B7 rs28365063 GG genotype statistically significantly discontinued treatment due to adverse events more often. Intermediate and extensive CYP2D6 metabolizers statistically significantly reported obstipation more often (P = 0.005). The effects of other studied polymorphisms on the risk of discontinuing treatment or the occurrence of adverse events were not statistically significant.
tramadol
genetski polimorfizmi
CYP2D6
UGT2B7
ABCC2
ABCB1
neželeni učinki
tramadol
genetic polymorphism
CYP2D6
UGT2B7
ABCC2
ABCB1
adverse effects
true
false
false
Slovenski jezik
Angleški jezik
Magistrsko delo/naloga
2019-09-11 07:46:31
2019-09-11 07:46:34
2022-08-22 03:41:00
0000-00-00 00:00:00
2019
0
0
0000-00-00
NiDoloceno
NiDoloceno
NiDoloceno
0000-00-00
0000-00-00
0000-00-00
167967
5195855
7731.pdf
7731.pdf
1
706AF5D778E4612A79E1C5C42B76E721
7bcd7ea2b979c61a4fbd7397e1efe94cdbe1e5934039b4ceee84a0a9b7fd9716
020a7635-a1b7-11eb-a523-00155dcfd717
https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=121613
Biotehniška fakulteta
0
0
0